within Pharmacolibrary.Drugs.ATC.C;

model C09BB10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.0009166666666666666,
    adminDuration  = 600,
    adminMass      = 180 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.25,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09BB10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>The fixed-dose combination of trandolapril (an angiotensin-converting enzyme inhibitor) and verapamil (a calcium channel blocker) is used in the management of hypertension in adults whose blood pressure is not adequately controlled by either agent alone. Both drugs act synergistically to reduce blood pressure; trandolapril by inhibiting angiotensin II formation and verapamil by relaxing vascular smooth muscle. The combination product is approved and available in several countries.</p><h4>Pharmacokinetics</h4><p>No published studies detailing combined pharmacokinetic parameters for the trandolapril and verapamil fixed-dose combination were found as of June 2024. The PK parameters presented here are rough estimates based on the PK of the individual drugs in healthy adults following oral administration.</p><h4>References</h4><ol><li><p>Reynolds, NA, et al., &amp; Keam, SJ (2005). Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. <i>Drugs</i> 65(13) 1893–1914. DOI:<a href=\"https://doi.org/10.2165/00003495-200565130-00011\">10.2165/00003495-200565130-00011</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16114984/\">https://pubmed.ncbi.nlm.nih.gov/16114984</a></p></li><li><p>Lambert Kuhn, E, et al., &amp; Bilbault, P (2016). Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report. <i>Journal of clinical pharmacy and therapeutics</i> 41(1) 104–105. DOI:<a href=\"https://doi.org/10.1111/jcpt.12355\">10.1111/jcpt.12355</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26813987/\">https://pubmed.ncbi.nlm.nih.gov/26813987</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09BB10;
